FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer
Maureen Caligiuri(Forma Therapeutics (United States)), Sylvie M. Guichard(Massachusetts Medical Society)
Cited by 30
Related Papers
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
|Molecular Cancer Therapeutics|2015|125